NEUROCRINE BIOSCIENCES, INC. AND as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 20, 2021First Supplemental Indenture • February 11th, 2022 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances) • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of December 20, 2021 (this “Supplemental Indenture”), among Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), as issuer, and U.S. Bank National Association, a national banking association organized under the laws of the United States of America, as trustee (the “Trustee”), to the Indenture, dated as of May 2, 2017 (as supplemented or otherwise modified prior to the date hereof, the “Indenture”), between the Company and the Trustee.
ContractCollaboration and License Agreement • February 11th, 2022 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances) • England
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT NEUROCRINE BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL
